CervoMed's Neflamapimod Increases Basal Forebrain Volume in DLB, Eyes Phase 3
CRVO sits 20% above its 52-week low of $3.51.
Summary
CervoMed announced positive new data from its RewinD-LB Phase 2b clinical trial for neflamapimod in Dementia with Lewy Bodies (DLB) at the 2026 AAN Annual Meeting. The data demonstrated that neflamapimod significantly increased basal forebrain volume and functional connectivity compared to placebo (p=0.022), a critical finding as basal forebrain atrophy is a primary driver of DLB progression. These results are highly material for CervoMed, a small-cap biotech, as they provide strong evidence that the drug acts on the underlying pathology of DLB, a condition with no approved treatments. The company plans to incorporate these findings into a planned Phase 3 trial for DLB patients, subject to financing, later this year. Traders will closely monitor updates regarding the financing and initiation of this pivotal Phase 3 study.
At the time of this announcement, CRVO was trading at $4.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $3.51 to $13.13. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.